via Penn Medicine
In a mouse study, researchers used nanotechnology and previous knowledge of a protein pathway to significantly reduce knee cartilage degeneration and pain
There is currently no cure for osteoarthritis, but a group of scientists believe they’ve discovered a method through which a simple knee injection could potentially stop the disease’s effects. These researchers showed that they could target a specific protein pathway in mice, put it into overdrive and halt cartilage degeneration over time. Building on that finding, they were able to show that treating mice with surgery-induced knee cartilage degeneration through the same pathway via the state of the art of nanomedicine could dramatically reduce the cartilage degeneration and knee pain. These findings were published in Science Translational Medicine.
“Our lab is one of the few in the world studying epidermal growth factor receptor (EGFR) signaling in cartilage and, from the beginning, we have found that EGFR deficiency or inactivation accelerates osteoarthritis progression in mice,” said Ling Qin, PhD, an associate professor of Orthopaedic Surgery. “Thus, we proposed that its activation could be used to treat osteoarthritis, and in this study, we’ve proven for the first time that over-activating it inside the knee blocks the progression of osteoarthritis.”
Qin explained that tests from the other labs that do work with EGFR have drawn “confusing and controversial” results. But Qin’s lab has consistently found the ties between osteoarthritis and EGFR deficiencies, which formed the bedrock of their hypothesis.
The researchers compared typical mice with those that had a molecule that bound to EGFR, called a ligand, that was over-overexpressed in chondrocytes, the building blocks of cartilage. This overexpression drives the over-activation of EGFR signaling in knee cartilage. When examining them, the mice with overexpressed HBEGF (the EGFR ligand) were found to consistently have enlarged cartilage, meaning that it wasn’t wearing away like the mice who had normal EGFR activity. Moreover, when these mice aged to adulthood, their cartilage was resistant to degeneration and other hallmarks of osteoarthritis, even if their knee’s meniscus was damaged.
To further prove that the over-activated EGFR was the reason for the mice’s resiliency, the researchers found that gefitinib treatments, which are designed to block EFGR function, took away the protection against cartilage degeneration.
With all of this knowledge gained, the researchers turned an eye toward potential clinical treatment solutions. In a new series of tests they created nanotherapeutics by attaching a potent EGFR ligand, transforming growth factor-alpha, onto synthetic nanoparticles, to inject into mice who already had cartilage damage in their knees.
“Free EGFR ligands have a short half-life and cannot be retained inside of a joint capsule due to their small size,” explained Zhiliang Cheng, PhD, a research associate professor in Penn Engineering and another of the co-corresponding authors on the paper. “Nanoparticles help to protect them from degradation, restrict them within the joint, reduce off-target toxicity, and carry them deep inside dense cartilage to reach chondrocytes.”
When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening, as well as eased knee pain. There also were no major side effects seen in the mice who were treated.
“While many of the technical aspects of this application still need to be worked out, the ability to stop or slow the course of osteoarthritis with an injection rather than surgery would dramatically change how we feel and function as we age and after injury,” said one of the study’s co- authors, Jaimo Ahn, MD, PhD, a former faculty member at Penn Medicine now chief of orthopaedic trauma and associate chair of orthopaedic surgery at the University of Michigan.
The treatment is likely some time away for human patients, but the nanoparticles used have already been clinically tested and deemed safe, which makes it easier to quickly translate to clinical use.
“There is a great unmet medical need for a disease-modifying osteoarthritis drug,” Qin said. “In the future, we will optimize the drug design and test it in large animals before proceeding to clinical trials. We hope our research could lead to a novel drug that will improve the health and well-being of the more than 27 million osteoarthritis patients in the United States.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Osteoarthritis
- Blood test finds knee osteoarthritis up to eight years before it appears on X-rays: Study
A blood test successfully predicted knee osteoarthritis at least eight years before tell-tale signs of the disease appeared on x-rays, Duke Health researchers report. In a study appearing in ...
- What is osteoarthritis? Here are 3 things to know about treatment
Osteoarthritis is inflammation of the joints that comes from years of wear and tear. Here are three things to know that may help you feel better.
- Strength training improves knee health, lowers risk of knee osteoarthritis: Study
The research team aimed to evaluate the relationship of a history of strength training with symptomatic and structural outcomes of knee OA. They conducted a retrospective, cross-s ...
- Diacerein, Resveratrol, Botulinum Toxin Disappoint in Knee Osteoarthritis
VIENNA — Data do not back the use of diacerein or resveratrol for managing the pain of knee osteoarthritis (OA), according to the results of two well-performed, multicenter, double-blind, randomized ...
- Several Novel Injectables Show Early Promise in Knee Osteoarthritis
Data on several novel injectable drugs were presented at the World Congress on Osteoarthritis, as well as updated data on the gene therapy XT-150.
Go deeper with Google Headlines on:
Osteoarthritis
[google_news title=”” keyword=”osteoarthritis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanotherapeutics
- Biomednewsbreaks Clene Inc. (NASDAQ: CLNN) Spotlighted In A Recent 'From Lab To Launch' Podcast Release
Clene (NASDAQ: CLNN) (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biophar ...
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington | Morningstar
Clene is pioneering catalytic nanotherapeutics to treat these diseases. We target improvement of mitochondrial function via the catalytic activity of our asset, CNM-Au8, to improve nicotinamide ...
- IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob ...
- ETH Day 2023
Such as the first intelligent surgical sealing material of its kind and the development of inorganic nanotherapeutics (Nanoglue). Endowed by the Fondation Jean- Jacques et Felicia Lopez- Loreta, this ...
- Axiom Space Ax-2 private spaceflight with SpaceX: Live updates
Rayyanah Barnawi, a Saudi research scientist, performed DNA nanotherapeutics (medical) mixing operations, and worked together with fellow Saudi astronaut Ali Alqarni on an advanced microscope ...
Go deeper with Google Headlines on:
Nanotherapeutics
[google_news title=”” keyword=”nanotherapeutics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]